In a study conducted by Li et al., out of the 29 metastatic cSCC samples evaluated, the majority of the activating mutations affected genes in the RAS/RAF/MEK/ERK pathway, such as HRAS, KRAS, the downstream kinase BRAF and the epidermal growth factor receptor (EGFR). This evidence concerns the gene HRAS and skin squamous cell carcinoma.